Histotripsy is an innovative, non-invasive treatment that uses focused ultrasound to precisely target and destroy liver tumors. This technique requires no incisions, radiation, or needles, typically causes minimal pain, and has fewer side effects and complications. It offers a promising alternative to traditional treatments, especially for patients who are not eligible for surgery.
Histotripsy technology has been approved by the U.S. FDA but is currently still in the clinical trial stage in Hong Kong. As such, this technology is not yet covered under VHIS at this stage. However, Bowtie is committed to supporting emerging medical technologies and promoting transparent pricing through packaged treatment plans. As a trial initiative, we are offering ex gratia coverage for Histotripsy-related treatment packages under the GHK Wellness Package.
If needed, you can contact GHK to arrange a doctor consultation and a “Histotripsy Comprehensive Evaluation Package” to determine whether this treatment is suitable for you.
After the evaluation, if you are confirmed to be eligible and proceed with the "Histotripsy Treatment – Liver Cancer Treatment Package," the cost of the "Histotripsy Comprehensive Evaluation Package" will also be full covered.